D3S-001 clinical trials
D3S-001 is named as an intervention in 2 current clinical trials in our USA, China, South Korea, Australia, Germany, France, Spain, Italy and Japan registers. 2 are recruiting patients now. All registered phases are Phase 1/2. The lead sponsor is D3 Bio (Wuxi) Co., Ltd. The most-studied condition is Advanced Solid Tumors With MAPK Pathway Mutations.
How D3S-001 works
All drug targets →- Colorectal cancerPhase 1/2
- Non-small cell lung carcinomaPhase 1/2
- Pancreatic ductal adenocarcinomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314913, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 14482, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for D3S-001
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for D3S-001
- ChEMBL
- CHEMBL5314913
- PubChem CID
- 167251905
- FDA UNII
- PFW9YLB86H
- Wikidata
- Q140529151
- Wikipedia
- Elisrasib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of D3S-001
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145 · KRAS P.G12C
|
Phase 1/2 | Recruiting | D3 Bio (Wuxi) Co., Ltd | USA, China, Germany, France, Spain, Italy, Japan, South Korea, Australia |
|
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
NCT05886920 · Advanced Solid Tumors With MAPK Pathway Mutations
|
Phase 1/2 | Recruiting | D3 Bio (Wuxi) Co., Ltd | USA, China, South Korea, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with D3S-001
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| D3 Bio (Wuxi) Co., Ltd | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about D3S-001 trials
How many clinical trials are testing D3S-001?
2 current trials in our USA, China, South Korea, Australia, Germany, France, Spain, Italy and Japan registers name D3S-001 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are D3S-001 trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in China, 2 with sites in South Korea, 2 with sites in Australia, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors D3S-001 clinical trials?
The lead sponsor is D3 Bio (Wuxi) Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how D3S-001 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how D3S-001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists D3S-001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.